Treatment Decisions: Taking Control

The sheer volume and complexity of the medical information that the newly diagnosed cancer patient must quickly absorb can be overwhelming. Often, decisions must be made in a hurry, and under great stress. It is not easy under these circumstances to make a careful and fully informed decision.

I offer phone consultations to clients who have bought a Moss Report on their particular type of cancer. A phone consultation can be enormously helpful in drawing up a treatment strategy and getting one's options clearly prioritized. This week, a client offered the following comment:

"Once again, Dr. Moss has provided excellent information and resources in a concise format including names, phone numbers and personal recommendations for therapies to consider that are specific to my diagnosis. He is totally supportive of my approach to use conventional medicine to deal with my current crisis and to use alternative therapies to ensure nothing else goes into crisis mode. He's also been extremely helpful in suggesting alternatives for the future that have excellent prospects for true remission. I can't thank him enough." - R.G.

 

We have Moss Reports on more than 240 different types of cancer. You can order a Moss Report and download it directly from our Web site, www.cancerdecisions.com.

To schedule an appointment for a phone consultation, please email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it , or call 1-800-980-1234 (814-238-3367 from outside the US).

We look forward to helping you.

Avastin - Your Money or Your Life

Almost four years ago, in February 2004, the Food and Drug Administration (FDA) granted approval to Avastin, a new kind of anti-cancer drug. In contrast to traditional chemotherapy, which indiscriminately kills all rapidly dividing cells (including healthy ones), Avastin works highly selectively. For this reason it is known as a ‘targeted' drug.

Several targeted drugs have now been approved for use in cancer, but Avastin was the first of its particular type to be licensed by the FDA. Avastin is what is known as an "angiogenesis inhibitor." Angiogenesis inhibitors are designed to work by preventing tumors from developing new blood vessels. Without an abundant blood supply, a tumor cannot obtain sufficient nutrients and consequently its growth rate is slowed.

The advent of targeted agents over the past few years seemed to promise a more rational and subtle approach to the treatment of cancer. Thirty years of chemotherapy have not appreciably dented the rate of cancer deaths worldwide. Clearly, a new approach is long overdue. Might targeted agents such as Avastin be the harbinger of a new era in cancer treatment?

Our report: "Avastin - Your Money Or Your Life" examines the clinical evidence that has been gathered to date on the use of Avastin in several common types of cancer including colorectal, breast and lung cancer. The report also documents the mounting evidence of Avastin' disturbing side effects, and analyzes the implications, both to individuals and to society, of enormously expensive targeted drugs such as Avastin. This report is one our Current Topics series, a growing list of reports focusing on subjects of importance in the field of cancer prevention and treatment. These reports, averaging 30 pages in length, can also be purchased and downloaded directly from our Web site.

To order "Avastin - Your Money Or Your Life" please click or go to:
http://www.cancerdecisions.com/031906.html

Other reports in our Current Topics series include:

• On Guard - Gardasil (A discussion of the anti-cervical cancer vaccine Gardasil)
  
  
• Do Antioxidants and Chemotherapy Conflict?
  
  
• Mammography, Biopsy and the Diagnosis of Breast Cancer
  
  
• Herceptin or Deceptin? (An evaluation of the use of Herceptin in breast cancer)
  
  
• The Politics of Hope: Andrew von Eschenbach and the Decline of the National Cancer Institute
  
  
• The Mexican Cancer Clinics in the Era of Evidence-Based Medicine